The Short Bowel Syndrome Market is bound to grow on a gracious note in the next 10 years. The healthcare vertical is shifting to “value” from “production”. This shift concerning collaboration (in place of competition) is expected to set new benchmarks in the Short Bowel Syndrome Market. This fast-moving environment is expected to take the healthcare vertical by storm in the next decade.

Short bowel syndrome affect the functional capability of intestine. Patients suffering from short bowel syndrome have a reduced ability to absorb trace elements, fats, vitamins, fluids, minerals and carbohydrates and can experience weight loss, malnutrition, diarrhea and dehydration.

Presently, there is no cure for short bowel syndrome and the treatment is targeted towards symptoms. In a few cases, short bowel syndrome can be life-threatening but usually, the disease can managed through effective medication.

Get Sample Copy of this Report @

Market Segmentation:

basis of drug type
  • Glucagon-like Peptide
  • Anti-Diarrheals
  • Histamine Blockers
  • Proton Pump Inhibitors
  • Growth Hormone
  • Others
basis of distribution channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Others

Rising awareness and availability of epidemiological data lead to the better management of short bowel disease. Further, rapid improvements in the field of healthcare have increased awareness regarding short bowel syndrome and thus, created opportunities.

Along with these, non-profit organizations are promoting research & development around short bowel syndrome in joint scientific research between the public sector and the private sector.

For the entire list of market players, request for Table of Content here @

The global short bowel syndrome treatment market has witnessed robust growth due to the increasing demand for drugs. The short bowel syndrome market is marked by the presence of limited manufacturers for approved therapies, which is paving way for huge opportunities in terms of market acquisitions and price flexibility.

Attributing to this, government bodies are directly taking part in encouraging local manufacturers through various initiatives. Apart from this, non-profit organizations are taking part in healthcare advocacy and public awareness.

Primary advocacy focuses on the improvement of the healthcare system, i.e. diagnosis, treatment, and support with comparatively less emphasis on research and drug development.

Pre-Book Right Now for Exclusive Analyst Support @

Key participants operating in the short bowel syndrome treatment market include Shire Plc, Merck & Company, Inc., Swedish Orphan Biovitrum AB, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca Plc, Johnson & Johnson, and others. Players mainly focus on collaborations and partnerships to keep pace with the competition and develop new products.

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales –